Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
First Claim
1. A method for the preparation of a Complex comprised of a VEGF Nucleic Acid Ligand comprising 2′
- -F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound, said method comprising;
a) identifying a VEGF Nucleic Acid Ligand from a Candidate Mixture of Nucleic Acids by the method comprising;
i) contacting the Candidate Mixture with VEGF, wherein Nucleic Acids having an increased affinity to VEGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture;
ii) partitioning the increased affinity VEGF Nucleic Acids from the remainder of the Candidate Mixture;
iii) amplifying the increased affinity VEGF Nucleic Acids to yield a ligand-enriched mixture of Nucleic Acids; and
b) associating said identified VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound.
2 Assignments
0 Petitions
Accused Products
Abstract
This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
-
Citations
17 Claims
-
1. A method for the preparation of a Complex comprised of a VEGF Nucleic Acid Ligand comprising 2′
- -F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound, said method comprising;
a) identifying a VEGF Nucleic Acid Ligand from a Candidate Mixture of Nucleic Acids by the method comprising;
i) contacting the Candidate Mixture with VEGF, wherein Nucleic Acids having an increased affinity to VEGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture;
ii) partitioning the increased affinity VEGF Nucleic Acids from the remainder of the Candidate Mixture;
iii) amplifying the increased affinity VEGF Nucleic Acids to yield a ligand-enriched mixture of Nucleic Acids; and
b) associating said identified VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
- -F-modified nucleotides and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound, said method comprising;
Specification